Press Release
« Back
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 57th American Society of Hematology Annual Meeting
Nov 05, 2015
Company to Host Third Quarter Earnings Conference Call to Review Financial Results, Business Updates as well as Provide an Overview of the ASH Abstract Data, on
Investor Reception to be Held on Monday December 7, 2015 from 7:45 pm - 9:00 pm ET at the
Presentations on TG-1101 and TGR-1202 at the ASH meeting include the following:
Clinical Posters:
- Title: Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
- Abstract Number: 1538
- Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
- Date and Time:
Saturday, December 5, 2015 ;5:30 PM- 7:30 PM ET - Location:
Orange County Convention Center , Hall A - Presenter:
Matthew Lunning , DO
- Title: A Phase I Trial of TGR-1202, a
Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia- Abstract Number: 2942
- Session: 642. CLL: Therapy, excluding Transplantation: Poster II
- Date and Time:
Sunday, December 6, 2015 ;6:00 PM-8:00 PM ET - Location:
Orange County Convention Center , Hall A - Presenter: Daruka Mahadevan, MD, PhD
- Title: Ublituximab (TG-1101), A Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With Ibrutinib is Highly Active in Patients With Relapsed And/Or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
- Abstract Number: 3980
- Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
- Date and Time:
Monday, December 7, 2015 ;6:00 PM- 8:00 PM ET - Location:
Orange County Convention Center , Hall A - Presenter:
Kathryn Kolibaba , MD
- Title: TGR-1202, a
Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma- Abstract Number: 4154
- Session: 642. CLL: Therapy, excluding Transplantation: Poster III
- Date and Time:
Monday, December 7, 2015 ;6:00 PM- 8:00 PM ET - Location:
Orange County Convention Center , Hall A - Presenter:
Owen O'Connor , MD, PhD
Non-Clinical Oral Presentation:
- Title: Disruption of the mTOR-eIF4F Axis By
Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas
- Abstract Number: 593
- Oral Session: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Novel Therapies and Targets in Lymphoma
- Date and Time:
Monday, December 7, 2015 ;10:30 AM - 12:00 PM ET - Presentation Time:
11:30 AM ET - Location:
Orange County Convention Center , Tangerine 1 (WF1) - Presenter:
Changchun Deng , MD, PhD
A copy of the above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org.
ABOUT TG THERAPEUTICS, INC.
Cautionary Statement
Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303, will not prove to be a safe and efficacious backbone for triple and quad combination therapies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
TGTX-G
CONTACT:Source:Jenna Bosco Director- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com
News Provided by Acquire Media